ArticleExperimental animals2026
Neuroprotective effect of safflower yellow in mice with cerebral ischemia reperfusion injury.
Article in Experimental animals, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Safflower yellow (SY), a bioactive compound from Carthamus tinctorius L., possesses potent antioxidant and anti-inflammatory properties and may exert protective effects on vulnerable brain regions during acute global ischemia. Therefore, this study aimed to evaluate the neuroprotective effects of SY against cerebral ischemia-reperfusion (IR) injury in mice, focusing on oxidative status, hippocampal neuronal survival, and white matter integrity. Forty male (Institute of Cancer Research) ICR mice were assigned to Sham-veh, IR-veh, IR-SY50, and IR-SY100 groups. Pretreatment with SY or vehicle was performed for 2 weeks before IR induction by 30-min bilateral common carotid artery occlusion and 24-h reperfusion. Brain infarct volume, oxidative status, and histological changes in the hippocampus and corpus callosum (CC) were evaluated. Significantly increased lipid peroxidation and cerebral infarction, depletion of catalase (CAT) activity, selective neuronal death in the Cornus Ammonis 1 (CA1) region, and loss of CC white matter integrity were clearly depicted after IR induction. Pretreatment with SY doses of 50 and 100 mg/kg significantly attenuated brain infarct volume, together with upregulated superoxide dismutase and catalase activities. Histological analysis revealed a dose-dependent therapeutic threshold. Only SY at 100 mg/kg significantly prevented neuronal death in the CA1 region and preserved CC white matter integrity. Pretreatment with SY exhibits neuroprotective effects against IR primarily by enhancing endogenous antioxidant defenses. Crucially, while biochemical improvements are achievable at lower doses, a higher therapeutic dose is required to preserve neuronal and white matter structural integrity in selectively vulnerable brain regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.